COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETs
ITM (COMPOSE) Phase III Clinical Trial: 177 LU-EDOTREOTIDE VS. Best Standard of Care in Well-Differentiated Aggressive G2 & G3 GEP-NETs
CLINICALTRIALS.GOV IDENTIFIER: NCT04919226
DRUG/TREATMENT: 177Lu-Edotreotide PRRT (Peptide Receptor Radionuclide Therapy) PRRT versus CAPTEM (Capecitabine and Temozolomide), Everolimus or FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Dr. Heloisa Soares Discusses COMPOSE: PRRT -LU-177 EDOTREOTIDE
Dr. Will Pegna Discusses COMPOSE: PRRT - LU-177 EDOTREOTIDE Starting at 9:04
ITM is sponsoring “COMPOSE,” an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs).
The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites.
Dr. Nicolas Schneider or Amanda Rotger at ITM